Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1

FASEB Journal

Volumn 15, Issue 1, 2001, Pages 115-122

  Shapiro, L ^a   Pott, G B ^a   Ralston, A H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Alpha 1 proteinase inhibitor; HIV 1; Interleukin 18; NF kappa B; Serine proteinase inhibitors

Indexed keywords

ALPHA 1 ANTITRYPSIN; CE 2072; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; GENE ACTIVATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

ADULT; ALPHA 1-ANTITRYPSIN; ANTI-HIV AGENTS; CELL LINE; FEMALE; HALF-LIFE; HELA CELLS; HIV CORE PROTEIN P24; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; NF-KAPPA B; SERINE PROTEINASE INHIBITORS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0035166723     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0311com     Document Type: Article

References (49)

1. Cultivation of human immunodeficiency virus from whole blood: Effect of anticoagulant and inoculum size on virus growth
2. HIV isolation from whole blood: A new approach to HIV detection
3. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
4. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
5. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposure
6. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood
7. Accidental hepatitis-B-surface-antigen-positive inoculations
8. Orogenital sex and the transmission of HIV among homosexual men
9. Human immunodeficiency virus and oral intercourse
10. Sexual practices and risk of infection by the human immunodeficiency virus
11. Risk factors for seroconversion to human immunodeficiency virus among male homosexuals
12. Minimal risk of transmission of AIDS-associated retrovirus infection by oralgenital contact
13. Saliva inhibits HIV-1 infectivity
14. Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus type 1 activity in vitro
15. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription
16. 1-antitrypsin deficiency
17. 1-antitrypsin: Molecular structure and the Pi system
18. α-antitrypsin: Molecular pathology, leukocytes, and tissue damage
19. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme
20. Emergence of dual resistance to zidovudine and lamivudine in clinical HIV-1 isolates from patients receiving zidovudine/lamivudine combination therapy
21. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line
22. Osmotic regulation of cytokine synthesis in vitro
23. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
24. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene
25. Interleukin 18 stimulates HIV type 1 in monocytic cells
26. Microculture assay for isolation of human immunodeficiency virus type 1 and for titration of infected peripheral blood mononuclear cells
27. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates
28. Preparation and properties of alpha 1-proteinase inhibitor concentrate from human plasma
29. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor α by transcriptional and post-transcriptional mechanisms
30. Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro
31. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons
32. A study of HIV RNA viral load in AIDS patients with bacterial pneumonia
33. Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase-3
34. Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat
35. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB
36. NF-κB: A pleiotropic mediator of inducible and tissue-specific gene control
37. α-1-andtrypsin defciency, emphysema, and liver disease
38. 1-antitrypsin deficiency
39. 1-antitrypsin PiZ
40. Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema
41. Interaction between a membrane-associated serine proteinase of U-937 monocytes and peptides from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) gp120 envelope glycoprotein
42. Identification of the U-937 membrane-associated proteinase interacting with the V3 loop of HIV-1 gp120 as cathepsin G
43. + lymphocytes immunologically reactive with antibody inhibiting syncytia induced by HIV-1
44. Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection
45. + lymphocytes is a novel binding protein of the V3 domain of HIV-1 envelope glycoprotein gp120
46. Inhibition of HIV-1 by modification of a host membrane protease
47. Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase
48. Antiretroviral therapy in adults: Updated recommendations of the international AIDS society-USA panel